Expression of SLC25A38 in leukemic cells from children with acute lymphoblastic leukemia.
10.7534/j.issn.1009-2137.2014.05.008
- Author:
Hua-Ying CHEN
1
;
Yan-Yan LU
1
;
Hong WEN
2
;
Quan-Yi LU
3
;
Yun-Wu ZHANG
4
;
Hua-Xi XU
5
Author Information
1. Department of Hematology, Zhongshan Hospital, Xiamen University, Xiamen 361004, Fujian Province, China.
2. Department of Pediatrics, The First Affiliated Hospital of Xiamen University, Xiamen 361003, Fujian Province, China. E-mail: wenhong711@aliyun.com.
3. Department of Hematology, Zhongshan Hospital, Xiamen University, Xiamen 361004, Fujian Province, China. E-mail: quanyilu@hotmail.com.
4. Institute of Neuroscienc, Xiamen University,Xiamen 361005, Fujian Province, China.
5. Institute of Neuroscienc, Xiamen University, Xiamen 361005, Fujian Province, China.
- Publication Type:Journal Article
- MeSH:
Child;
Humans;
Immunophenotyping;
Leukocyte Count;
Mitochondrial Membrane Transport Proteins;
metabolism;
Precursor Cell Lymphoblastic Leukemia-Lymphoma;
metabolism;
RNA, Messenger;
Real-Time Polymerase Chain Reaction
- From:
Journal of Experimental Hematology
2014;22(5):1230-1234
- CountryChina
- Language:Chinese
-
Abstract:
This study was aimed to investigate the SLC25A38 expression in pediatric patients with acute lymphoblastic leukemia (ALL) and its clinical significance. A total of 23 newly diagnosed ALL pedictric patients were enrolled in test group, 10 pediatric patients with non-hematologic malignancies were selected as control group. The expression in protein and mRNA levels of SLC25A38 were detected by Western blot and real-time PCR respectively. The results showed that the SLC25A38 protein was positive in 8 of 23 pediatric ALL patients (34.78%), while no positive case was found in 10 controls. The relative expression level of SLC25A38 mRNA was 0.4673 ± 0.05344 in SLC25A38-protein positive group of ALL patients, while that was 1.296 ± 0.2517 in SLC25A38-protein negative group of ALL patients. The expression level of SLC25A38 mRNA in SLC25A38-protein positive group was significantly lower than that in negative group (P = 0.001) . No statistically significant difference was found in comparison of SLC25A38-protein negative group of ALL patients with the control group (P = 0.1097). The analysis of clinical data showed that there were significantly differences in sex, immunophenotype, initial peripheral white blood cell count and LDH between the SLC25A38-protein positive and SLC25A38-protein negative groups (P < 0.05). It is concluded that as a novel protein, SLC25A38 highly expressed in pediatric ALL patients, indicating that SLC25A38 may serve as a molecular marker and potential therapeutic target for acute lymphoblastic leukemia in children.
